Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Black study participants switched from a regimen with two nucleoside/nucleotide reverse transcriptase inhibitors plus one other HIV drug.
Gilead Sciences presented findings from several studies of the single-tablet antiretroviral regimen at a recent scientific meeting.
Pooled results from recent studies found a high rate of full viral suppression and no major safety concerns.
Researchers are surprised and concerned that a strain of HIV that is so broadly resistant to treatment even has the capacity to transmit.
People who switched from tenofovir disoproxil fumarate to tenofovir alafenamide gained weight regardless of other meds.
This is especially the case for people globally who don’t have access to such newer regimens.
Advocates claim Gilead and others unfairly limited competition for HIV combination pills.
Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.
Researchers at George Washington University take a look.
The latest revision recognizes the importance of treatment as prevention.
The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.
This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.
The newer tenofovir formulation can raise cholesterol and triglyceride levels, but these changes are reversible.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.